Clinical Trials Browser

Has results × Has announcements × Lenalidomide × Clear all

NCT03710603 2026-02-10

Perseus

Phase 3 Active not recruiting

709 enrolled 17 charts 1 FDA

Multiple Myeloma

NCT04680052 2025-12-22

InMIND

Phase 3 Active not recruiting

654 enrolled 40 charts 1 FDA

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02252172 2025-10-20

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Phase 3 Completed

737 enrolled 30 charts 1 FDA

Multiple Myeloma

NCT01996865 2025-07-10

MAGNIFY

Phase 3 Completed

503 enrolled 18 charts 1 FDA

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Phase 2 Completed

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT01938001 2023-02-22

AUGMENT

Phase 3 Completed

358 enrolled 18 charts 1 FDA

Lymphoma, Non-Hodgkin